Related references
Note: Only part of the references are listed.Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL
Peter Martin et al.
BLOOD (2022)
SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool
Elizabeth A. Brem et al.
JOURNAL OF GERIATRIC ONCOLOGY (2022)
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
Franck Morschhauser et al.
BLOOD (2021)
First-line treatment of double-hit and triple-hit lymphomas: Survival and tolerance data from a retrospective multicenter French study
Marie-Charlotte Laude et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP
Joo Y. Song et al.
CLINICAL CANCER RESEARCH (2021)
A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death
Sophia Ceder et al.
EMBO MOLECULAR MEDICINE (2021)
Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas
Devin Dersh et al.
IMMUNITY (2021)
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
David A. Sallman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Compromised counterselection by FAS creates an aggressive subtype of germinal center lymphoma
Raud Razzaghi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
GNA13 regulates BCL2 expression and the sensitivity of GCB-DLBCL cells to BCL2 inhibitors in a palmitoylation-dependent manner
Zhizhou Xia et al.
CELL DEATH & DISEASE (2021)
Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors
Vignesh Shanmugam et al.
BLOOD ADVANCES (2021)
Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4+ Diffuse Large B-Cell Lymphoma Cells
Aida Falgas et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2021)
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study
Erlene K. Seymour et al.
CLINICAL CANCER RESEARCH (2021)
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study
Sarah C. Rutherford et al.
LANCET HAEMATOLOGY (2021)
Discovery and resistance mechanism of a selective CDK12 degrader
Baishan Jiang et al.
NATURE CHEMICAL BIOLOGY (2021)
Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: A multi-center analysis
Christopher R. D'Angelo et al.
HEMATOLOGICAL ONCOLOGY (2021)
A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas
Jie Ji et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis
Yao-Hui Huang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Transcriptional regulation of memory B cell differentiation
Brian J. Laidlaw et al.
NATURE REVIEWS IMMUNOLOGY (2021)
A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models
Aida Falgas et al.
HAEMATOLOGICA (2020)
Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas
Xuan Zhang et al.
LEUKEMIA (2020)
CD95/Fas and metastatic disease: What does not kill you makes you stronger
Jean Philippe Guegan et al.
SEMINARS IN CANCER BIOLOGY (2020)
Clinical significance of 'double-hit' and 'double-expression' lymphomas
Zhiping Ma et al.
JOURNAL OF CLINICAL PATHOLOGY (2020)
Multiple Synthetic Routes to the Mini-Protein Omomyc and Coiled-Coil Domain Truncations
Zachary Z. Brown et al.
JOURNAL OF ORGANIC CHEMISTRY (2020)
STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas
Roberto Tamma et al.
LEUKEMIA & LYMPHOMA (2020)
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy
Stephen D. Smith et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas
Yuka Tanaka et al.
CANCER SCIENCE (2020)
Selinexor (KTP-330)-a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL)
Sharon Ben-Barouch et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Perspectives on chemotherapy for the management of double-hit lymphoma
Taha Al-Juhaishi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Biomarker profile for prediction of response to SMAC mimetic monotherapy in pediatric precursor B-cell acute lymphoblastic leukemia
Julia Zinngrebe et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Genomic Landscape of Waldenstrom Macroglobulinemia and Its Impact on Treatment Strategies
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit
Francesco Cucco et al.
LEUKEMIA (2020)
TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma
Daisuke Ennishi et al.
NATURE MEDICINE (2020)
Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20
Xu-Wen Guan et al.
CELL DEATH & DISEASE (2020)
The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy
Jessica Michie et al.
CELLS (2020)
Rocaglates Induce Gain-of-Function Alterations to eIF4A and eIF4F
Jennifer Chu et al.
CELL REPORTS (2020)
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report
Stuart E. Lacy et al.
BLOOD (2020)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia
Pau Montesinos et al.
FUTURE ONCOLOGY (2020)
Molecular Risk Stratification in Aggressive B-Cell Lymphomas
Zachary A. K. Frosch et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
MYC protein stability is negatively regulated by BRD4
Ballachanda N. Devaiah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc
Daniel Masso-Valles et al.
CELLS (2020)
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL
Marco Haselager et al.
BLOOD (2020)
Copanlisib for the treatment of adults with relapsed follicular lymphoma
Massimo Magagnoli et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)
Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type
Valdemar Priebe et al.
CANCERS (2020)
BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression
Thomas E. C. Cummin et al.
BLOOD ADVANCES (2020)
XPO1-dependent nuclear export as a target for cancer therapy
Nancy G. Azizian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements Clinicopathologic Features of 51 Cases in a Single Institution of South China
Jijun Zhang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL
Carlos Balinas-Gavira et al.
LEUKEMIA (2020)
Pharmacological disruption of the Notch transcription factor complex
Rajwinder Lehal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Notch1 in Cancer Therapy: Possible Clinical Implications and Challenges
L. Gharaibeh et al.
MOLECULAR PHARMACOLOGY (2020)
Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis
Daniel Doheny et al.
ONCOGENE (2020)
A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
Qiuyun Luo et al.
ONCOLOGY RESEARCH (2020)
Targeting N-myristoylation for therapy of B-cell lymphomas
Erwan Beauchamp et al.
NATURE COMMUNICATIONS (2020)
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade
Guangchuan Wang et al.
CANCER DISCOVERY (2020)
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes
Hanna Scholze et al.
BLOOD ADVANCES (2020)
Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma
Rong Shen et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
E3 Ubiquitin Ligase TRIP12: Regulation, Structure, and Physiopathological Functions
Manon Brunet et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
Manman Deng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Notch Inhibition in Cancer: Challenges and Opportunities
Doriano Fabbro et al.
CHIMIA (2020)
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics
Pallawi Torka et al.
BLOOD ADVANCES (2020)
The CRL3BTBD9 E3 ubiquitin ligase complex targets TNFAIP1 for degradation to suppress cancer cell migration
Lihui Li et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Selective delivery of T22-PE24-H6 to CXCR4+ diffuse large B-cell lymphoma cells leads to wide therapeutic index in a disseminated mouse model
Aida Falgas et al.
THERANOSTICS (2020)
Feasibility of CXCR4-Directed Radioligand Therapy in Advanced Diffuse Large B-Cell Lymphoma
Constantin Lapa et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Andrew D. Zelenetz et al.
BLOOD (2019)
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype
James Godfrey et al.
BLOOD (2019)
Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2
James K. Godfrey et al.
CANCER (2019)
Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures
Weiyan Cheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways
Vera Magistroni et al.
HAEMATOLOGICA (2019)
Germinal center-derived lymphomas: The darkest side of humoral immunity
Coraline Mlynarczyk et al.
IMMUNOLOGICAL REVIEWS (2019)
Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma
Moo-Kon Song et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives
Hui Cong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma
Binu K. Sasi et al.
LEUKEMIA (2019)
Emerging epigenetic-modulating therapies in lymphoma
David Sermer et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Inhibitory effects of bortezomib in a subcutaneous tumor model of H22 mouse hepatocarcinoma cells
Mingao Zhu
PATHOLOGY RESEARCH AND PRACTICE (2019)
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
Daisuke Ennishi et al.
CANCER DISCOVERY (2019)
Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
Jennifer K. Lue et al.
CLINICAL CANCER RESEARCH (2019)
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies et al.
LANCET ONCOLOGY (2019)
Genetic alterations and their clinical implications in DLBCL
Yi Miao et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
C10ORF12 modulates PRC2 histone methyltransferase activity and H3K27me3 levels
Yi Shi et al.
ACTA PHARMACOLOGICA SINICA (2019)
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL
Andre Goy et al.
BLOOD (2019)
Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3
Shidong Lv et al.
EPIGENETICS (2019)
The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis
Michelle A. Mintz et al.
IMMUNITY (2019)
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Weiping Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma
Milos D. Miljkovic et al.
LEUKEMIA & LYMPHOMA (2019)
The Unsolved Puzzle of c-Rel in B Cell Lymphoma
Maike Kober-Hasslacher et al.
CANCERS (2019)
γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
Margot J. Pont et al.
BLOOD (2019)
Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma
Stefanie N. Meyer et al.
IMMUNITY (2019)
The CXCR4-CXCL12-Axis Is of Prognostic Relevance in DLBCL and Its Antagonists Exert Pro-Apoptotic Effects In Vitro
Katrin Pansy et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium
Andreas Rosenwald et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
Zachary A. K. Frosch et al.
BLOOD (2019)
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Longchuan Bai et al.
CANCER CELL (2019)
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy
Huiying Han et al.
CANCER CELL (2019)
Depletion of the transcriptional coactivators CREB-binding protein or EP300 downregulates CD20 in diffuse large B-cell lymphoma cells and impairs the cytotoxic effects of anti-CD20 antibodies
Annarita Scialdone et al.
EXPERIMENTAL HEMATOLOGY (2019)
Proteasomal cysteine deubiquitinase inhibitor b-AP15 suppresses migration and induces apoptosis in diffuse large B cell lymphoma
Liling Jiang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma
Yuanhui Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL
Kamil Bojarczuk et al.
BLOOD (2019)
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Daisuke Ennishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy
Chulin Sha et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
Stephen M. Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Mechanistic insights revealed by a UBE2A mutation linked to intellectual disability
Juliana Ferreira de Oliveira et al.
NATURE CHEMICAL BIOLOGY (2019)
Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein
Haibin Zhou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?
Ilaria Saltarella et al.
NEOPLASIA (2019)
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
Isha Kapoor et al.
CELL DEATH & DISEASE (2019)
EZH2/Bcl-2 Coexpression Predicts Worse Survival in Diffuse Large B-cell Lymphomas and Demonstrates Poor Efficacy to Rituximab in Localized Lesions
Yujie Deng et al.
JOURNAL OF CANCER (2019)
Induction of autophagy and autophagy-dependent apoptosis in diffuse large B-cell lymphoma by a new antimalarial artemisinin derivative, SM1044
Chunyan Cheng et al.
CANCER MEDICINE (2018)
42OA phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas
W Harb et al.
ANNALS OF ONCOLOGY (2018)
The tumor suppressive TGF-β/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma
Anna Stelling et al.
BLOOD (2018)
TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma
Alexander Jethwat et al.
BLOOD (2018)
Double-hit DLBCL: should we limit FISH testing?
Christiane Copie-Bergman
BLOOD (2018)
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology
David W. Scott et al.
BLOOD (2018)
Targeting c-Myc: JQ1 as a promising option for c-Myc-amplified esophageal squamous cell carcinoma
Jingyuan Wang et al.
CANCER LETTERS (2018)
Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Lan V. Pham et al.
CLINICAL CANCER RESEARCH (2018)
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
Victor Yazbeck et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies
Amnon Peled et al.
CYTOKINE (2018)
Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
Ellen D. McPhail et al.
HAEMATOLOGICA (2018)
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoine Italiano et al.
LANCET ONCOLOGY (2018)
MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas
Wenting Huang et al.
MODERN PATHOLOGY (2018)
A multiprotein supercomplex controlling oncogenic signalling in lymphoma
James D. Phelan et al.
NATURE (2018)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
Jianfeng Shen et al.
NATURE MEDICINE (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma
A. Esteve-Arenys et al.
ONCOGENE (2018)
FOXO in B-cell lymphopoiesis and B cell neoplasia
Alexey Ushmorov et al.
SEMINARS IN CANCER BIOLOGY (2018)
CXCR4 can induce PI3Kδ inhibitor resistance in ABC DLBCL
Joo Hyun Kim et al.
BLOOD CANCER JOURNAL (2018)
BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor
Hatice Gulcin Ozer et al.
CANCER DISCOVERY (2018)
Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
Ellen D. McPhail et al.
HAEMATOLOGICA (2018)
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial
John Mascarenhas et al.
JAMA ONCOLOGY (2018)
Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase 1b dose-finding study
S. de Vos et al.
ANNALS OF ONCOLOGY (2018)
Double hit lymphoma: How do we define it and how do we treat it?
Bridgin Merron et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2018)
MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis
Paola Brescia et al.
CANCER CELL (2018)
Interim Update from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
John Pagel et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
The safety of bortezomib for the treatment of multiple myeloma
Guldane Cengiz Seval et al.
EXPERT OPINION ON DRUG SAFETY (2018)
The molecular details of cytokine signaling via the JAK/STAT pathway
Rhiannon Morris et al.
PROTEIN SCIENCE (2018)
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies
Sean Caenepeel et al.
CANCER DISCOVERY (2018)
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
Guenter Krause et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells
Aditi Shastri et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas
Yuan Ren et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Matthew J. Reilley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The Novel HDAC Inhibitor Chidamide Synergizes with Rituximab to Inhibit DLBCL Tumor Growth in Vitro and In Vivo By up-Regulating CD20 Expression
Xu-Wen Guan et al.
BLOOD (2018)
Targeting oncogenic Myc as a strategy for cancer treatment
Hui Chen et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2018)
Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients
L. K. Schoch et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma
Kyle Runckel et al.
BLOOD ADVANCES (2018)
Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice
Ayana Kon et al.
BLOOD (2018)
The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling
Jin Li et al.
BLOOD (2017)
Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
Pierre Sesques et al.
BLOOD (2017)
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy
Massimiliano Salati et al.
HEMATOLOGICAL ONCOLOGY (2017)
A novel glycan modifies the flagellar filament proteins of the oral bacterium Treponema denticola
Kurni Kurniyati et al.
MOLECULAR MICROBIOLOGY (2017)
BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire
Zeynab Najafova et al.
NUCLEIC ACIDS RESEARCH (2017)
CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
Yanwen Jiang et al.
CANCER DISCOVERY (2017)
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus
Ramiro Vazquez et al.
ONCOTARGET (2017)
The role of p53 in cancer drug resistance and targeted chemotherapy
Karin Hientz et al.
ONCOTARGET (2017)
Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma
Leo Meriranta et al.
HAEMATOLOGICA (2017)
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
Yasuhiro Oki et al.
HAEMATOLOGICA (2017)
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation
Alex F. Herrera et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
Daniel J. Landsburg et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Catherine Thieblemont et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Matthew S. Davids et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas
Andrea Piunti et al.
NATURE MEDICINE (2017)
Proteasome inhibitors in cancer therapy
Elisabet E. Manasanch et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Marked for death: targeting epigenetic changes in cancer
Sophia Xiao Pfister et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
Anella Yahiaoui et al.
PLOS ONE (2017)
Inactivation of CREBBP expands the germinal center B cell compartment, down-regulates MHCII expression and promotes DLBCL growth
Hind Hashwah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma
Jiyuan Zhang et al.
CANCER DISCOVERY (2017)
Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition
Joyoti Dey et al.
SCIENTIFIC REPORTS (2017)
Deltex-1 mutations predict poor survival in diffuse large B-cell lymphoma
Leo Meriranta et al.
HAEMATOLOGICA (2017)
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
Yasuhiro Oki et al.
HAEMATOLOGICA (2017)
Strategies to Inhibit Myc and Their Clinical Applicability
Jonathan R. Whitfield et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2017)
The BET-Bromodomain Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression
Zhenqian Wu et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor
Daisuke Honma et al.
CANCER SCIENCE (2017)
Tonic B-cell receptor signaling in diffuse large B-cell lymphoma
Ondrej Havranek et al.
BLOOD (2017)
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma
Connie L. Batlevi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma
Jinfen Wang et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
Identifying and enriching platelet-producing human stem cell-derived megakaryocytes using factor V uptake
Xiuli Sim et al.
BLOOD (2017)
A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies
Shu-Hui Liu et al.
BLOOD ADVANCES (2017)
Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas
Shyril O'Steen et al.
CANCER RESEARCH (2017)
PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma
Lakshmi Nayak et al.
BLOOD (2017)
Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice
Idoia Garcia-Ramirez et al.
BLOOD (2017)
Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact
Daisuke Ennishi et al.
BLOOD (2017)
Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy
Reem Karmali et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas
Maciej Szydlowski et al.
BLOOD (2016)
Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
Ryan D. Morin et al.
CLINICAL CANCER RESEARCH (2016)
Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2-and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma
Magdalena Klanova et al.
CLINICAL CANCER RESEARCH (2016)
MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis
Shaoying Li et al.
HISTOPATHOLOGY (2016)
Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
Qing Ye et al.
ONCOTARGET (2016)
p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function
Zijun Y. Xu-Monette et al.
AGING-US (2016)
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma
Sarit E. Assouline et al.
BLOOD (2016)
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
Konstantinos Georgiou et al.
BLOOD (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704
Soham D. Puvvada et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells
Michael Boice et al.
CELL (2016)
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma
Zijun Y. Xu-Monette et al.
CLINICAL CANCER RESEARCH (2016)
Idelalisib for the treatment of non-Hodgkin lymphoma
Solomon A. Graf et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Kelch-like Protein 21 (KLHL21) Targets IB Kinase- to Regulate Nuclear Factor -Light Chain Enhancer of Activated B Cells (NF-κB) Signaling Negatively
Zhu-Zhong Mei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Bromodomain 4: a cellular Swiss army knife
Ballachanda N. Devaiah et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
Quadruplex Nucleic Acids as Novel Therapeutic Targets
Stephen Neidle
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma
M-L Nairismagi et al.
LEUKEMIA (2016)
BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members
Simon J. Hogg et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2
Daniel J. Hodson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Cortical dynamics during cell motility are regulated by CRL3KLHL21 E3 ubiquitin ligase
Thibault Courtheoux et al.
NATURE COMMUNICATIONS (2016)
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study
Sandy Amorim et al.
LANCET HAEMATOLOGY (2016)
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study
Christiane Copie-Bergman et al.
BLOOD (2015)
Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenstroom macroglobulinaemia tumour cells
Kasyapa Chitta et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis
Christina Howlett et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Protein Lysine Acetylation by p300/CBP
Beverley M. Dancy et al.
CHEMICAL REVIEWS (2015)
Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation
Haowei Sun et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Oral Debio 1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia-Results of a Phase I Dose-Escalation Study
John F. DiPersio et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Everolimus in diffuse large B-cell lymphomas
Michele Merli et al.
FUTURE ONCOLOGY (2015)
PI3 Kinase and FOXO1 Transcription Factor Activity Differentially Control B Cells in the Germinal Center Light and Dark Zones
Sandrine Sander et al.
IMMUNITY (2015)
Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study
Grzegorz S. Nowakowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1
L. Li et al.
LEUKEMIA (2015)
SRSF2 Is Essential for Hematopoiesis, and Its Myelodysplastic Syndrome-Related Mutations Dysregulate Alternative Pre-mRNA Splicing
Yukiko Komeno et al.
MOLECULAR AND CELLULAR BIOLOGY (2015)
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review
Rosalba Camicia et al.
MOLECULAR CANCER (2015)
Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma
Lu Jiang et al.
NATURE GENETICS (2015)
Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis
Jiyuan Zhang et al.
NATURE MEDICINE (2015)
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development
Ana Ortega-Molina et al.
NATURE MEDICINE (2015)
CD70: An emerging target in cancer immunotherapy
J. Jacobs et al.
PHARMACOLOGY & THERAPEUTICS (2015)
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
David Hong et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma
Ryan M. Young et al.
SEMINARS IN HEMATOLOGY (2015)
Prognostic impact of c-Rel nuclear expression and REL amplification and crosstalk between c-Rel and the p53 pathway in diffuse large B-cell lymphoma
Ling Li et al.
ONCOTARGET (2015)
Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma
Jiao Ma et al.
ONCOTARGET (2015)
Activating STAT6 mutations in follicular lymphoma
Mehmet Yildiz et al.
BLOOD (2015)
CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival
Maria Jose Moreno et al.
JOURNAL OF PATHOLOGY (2015)
TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations
Niklas Gebauer et al.
LEUKEMIA & LYMPHOMA (2015)
Oncogenic Y641 mutations in EZH2 prevent Jak2/β-TrCP-mediated degradation
A. A. Sahasrabuddhe et al.
ONCOGENE (2015)
Therapeutic Targeting of the JAK/STAT Pathway
Saara Aittomaki et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2014)
Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma
Hongxiu Li et al.
BLOOD (2014)
A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis
Tobias Berg et al.
BLOOD (2014)
Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients
Noel F. C. C. de Miranda et al.
BLOOD (2014)
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
Adam M. Petrich et al.
BLOOD (2014)
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma
Vicente Fresquet et al.
BLOOD (2014)
A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma (vol 165, pg 768, 2014)
Michinori Ogura
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Double hit lymphoma: the MD Anderson Cancer Center clinical experience
Yasuhiro Oki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma
Naoki Kaneko et al.
CLINICAL CANCER RESEARCH (2014)
MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations
Mette O. Pedersen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase
Matthew S. Davids et al.
FUTURE ONCOLOGY (2014)
Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma
Sietse M. Aukema et al.
HAEMATOLOGICA (2014)
B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies
Jose P. Vaque et al.
HAEMATOLOGICA (2014)
Small Molecules Targeting c-Myc Oncogene: Promising Anti-Cancer Therapeutics
Bing-Jia Chen et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2014)
Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies
Stephen M. Condon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Sixteenth Biannual Report of the Cochrane Haematological Malignancies Group: Focus on Non-Hodgkin's Lymphoma
Michaela Rancea et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial
Umberto Vitolo et al.
LANCET ONCOLOGY (2014)
Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma
Jagan R. Muppidi et al.
NATURE (2014)
Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis
Arianna Sabo et al.
NATURE (2014)
ARID1B is a specific vulnerability in ARID1A-mutant cancers
Katherine C. Helming et al.
NATURE MEDICINE (2014)
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Peter E. Czabotar et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
Richard J. Young et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
The Truncate Mutation of Notch2 Enhances Cell Proliferation through Activating the NF-κB Signal Pathway in the Diffuse Large B-Cell Lymphomas
Xinxia Zhang et al.
PLOS ONE (2014)
Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells
Elayne Hondares et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC
Steven H. Swerdlow
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
Oct2 and Obf1 as facilitators of B:T cell collaboration during a humoral immune response
Lynn Corcoran et al.
FRONTIERS IN IMMUNOLOGY (2014)
The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer
Greg Coffey et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Double-hit B-cell Lymphomas With BCL6 and MYC Translocations Are Aggressive, Frequently Extranodal Lymphomas Distinct From BCL2 Double-hit B-cell Lymphomas
Raju K. Pillai et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma
Paola Bonetti et al.
BLOOD (2013)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu et al.
BLOOD (2013)
Analysis of FOXO1 mutations in diffuse large B-cell lymphoma
Diane L. Trinh et al.
BLOOD (2013)
A capture-sequencing strategy identifies IRF8, EBF1, and APRIL as novel IGH fusion partners in B-cell lymphoma
Hakim Bouamar et al.
BLOOD (2013)
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing
Ryan D. Morin et al.
BLOOD (2013)
Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
Ling-Hua Zhang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Wendy Beguelin et al.
CANCER CELL (2013)
The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma
P. Bertrand et al.
GENES CHROMOSOMES & CANCER (2013)
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
Alexandra Valera et al.
HAEMATOLOGICA (2013)
Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development
Qingjie Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
M. Wang et al.
LEUKEMIA (2013)
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
Cigall Kadoch et al.
NATURE GENETICS (2013)
MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma
Carol Y. Ying et al.
NATURE IMMUNOLOGY (2013)
Targeting pathological B cell receptor signalling in lymphoid malignancies
Ryan M. Young et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Genetic heterogeneity of diffuse large B-cell lymphoma
Jenny Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma
Matthias Pfeifer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL)
Olga Ritz et al.
ONCOTARGET (2013)
Disruption of Myc-Max Heterodimerization with Improved Cell-Penetrating Analogs of the Small Molecule 10074-G5
Huabo Wang et al.
ONCOTARGET (2013)
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application
Muhammad Furqan et al.
BIOMARKER RESEARCH (2013)
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies
Zijun Y. Xu-Monette et al.
BLOOD (2012)
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu-Monette et al.
BLOOD (2012)
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells
Ze Tian et al.
BLOOD (2012)
FOXO1 is a tumor suppressor in classical Hodgkin lymphoma
Linka Xie et al.
BLOOD (2012)
TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma
David W. Scott et al.
BLOOD (2012)
Inhibitors of B-Cell Receptor Signaling for Patients With B-Cell Malignancies
Michael Y. Choi et al.
CANCER JOURNAL (2012)
Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl
G. Monaco et al.
CELL DEATH AND DIFFERENTIATION (2012)
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Marie Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
B and T cells collaborate in antiviral responses via IL-6, IL-21, and transcriptional activator and coactivator, Oct2 and OBF-1
Alex Karnowski et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological Impact
Joshua C. Black et al.
MOLECULAR CELL (2012)
BCL2 mutations in diffuse large B-cell lymphoma
J. M. Schuetz et al.
LEUKEMIA (2012)
Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: A clinicopathological study
Neerja Vajpayee et al.
LEUKEMIA RESEARCH (2012)
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Roland Schmitz et al.
NATURE (2012)
Histone methylation: a dynamic mark in health, disease and inheritance
Eric L. Greer et al.
NATURE REVIEWS GENETICS (2012)
MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20)
Sang-Woo Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Biological Prognostic Markers in Diffuse Large B-Cell Lymphoma
Anamarija M. Perry et al.
CANCER CONTROL (2012)
Functional Analysis of In-frame Indel ARID1A Mutations Reveals New Regulatory Mechanisms of Its Tumor Suppressor Functions
Bin Guan et al.
NEOPLASIA (2012)
Sepantronium Bromide (YM155) Enhances Response of Human B-Cell Non-Hodgkin Lymphoma to Rituximab
Aya Kita et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
Damian B. Yap et al.
BLOOD (2011)
Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma
Madhavi Challa-Malladi et al.
CANCER CELL (2011)
Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth
Denis Drygin et al.
CANCER RESEARCH (2011)
Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies
Loic Ysebaert et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma
Monica Civallero et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Mysterious link between iron overload and CDKN2A/2B
Shinya Toyokuni
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION (2011)
A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment
Qian Cai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies
Jon C. Aster et al.
JOURNAL OF PATHOLOGY (2011)
The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells
Brian A. Zabel et al.
MOLECULAR CANCER (2011)
Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
Stephen M. Ansell et al.
LANCET ONCOLOGY (2011)
GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia
X. Meng et al.
LEUKEMIA (2011)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
Laura Pasqualucci et al.
NATURE (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
The sphingosine 1-phosphate receptor S1P2 maintains the homeostasis of germinal center B cells and promotes niche confinement
Jesse A. Green et al.
NATURE IMMUNOLOGY (2011)
Kruppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression
Geoffrey T. Hart et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma
Feng Chen et al.
CELLULAR ONCOLOGY (2011)
EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
Irina Velichutina et al.
BLOOD (2010)
The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling
Mirza Suljagic et al.
BLOOD (2010)
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
Derek Yecies et al.
BLOOD (2010)
CXCL12 Mediates Immunosuppression in the Lymphoma Microenvironment after Allogeneic Transplantation of Hematopoietic Cells
Christoph Duerr et al.
CANCER RESEARCH (2010)
Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma
Christopher J. Stasik et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Bcl-2 and Bax Interact via the BH1-3 Groove-BH3 Motif Interface and a Novel Interface Involving the BH4 Motif
Jingzhen Ding et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
Leandro C. Cerchietti et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization
Dana M. Clausen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
Kieron Dunleavy et al.
BLOOD (2009)
Targeted Disruption of the S1P2 Sphingosine 1-Phosphate Receptor Gene Leads to Diffuse Large B-Cell Lymphoma Formation
Giorgio Cattoretti et al.
CANCER RESEARCH (2009)
Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma
Suk-young Lee et al.
CANCER SCIENCE (2009)
Functional, Structural, and Genetic Evaluation of 20 CDKN2A Germ Line Mutations Identified in Melanoma-Prone Families or Patients
Caroline Kannengiesser et al.
HUMAN MUTATION (2009)
Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells
Uta Ferch et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
IFN Regulatory Factor 8 Regulates MDM2 in Germinal Center B Cells
Jeff X. Zhou et al.
JOURNAL OF IMMUNOLOGY (2009)
Transcription activity is required for p53-dependent tumor suppression
O. Gaidarenko et al.
ONCOGENE (2009)
Expression of the interferon regulatory factor 8/ICSBP-1 in human reactive lymphoid tissues and B-cell lymphomas: A novel germinal center marker
Antonio Martinez et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Enzastaurin
Yi-Bin Chen et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-Cell lymphoma
O. Ritz et al.
LEUKEMIA (2008)
Foxo1 directly regulates the transcription of recombination-activating genes during B cell development
Rupesh H. Amin et al.
NATURE IMMUNOLOGY (2008)
The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation
Shwu-Yuan Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
Michael J. Robertson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas
Katia Lacrima et al.
LEUKEMIA & LYMPHOMA (2007)
The JAK-STAT signaling pathway: Input and output intergration
Peter J. Murray
JOURNAL OF IMMUNOLOGY (2007)
Establishment of a novel B-cell lymphoma cell line with suppressed growth by gamma-secretase inhibitors
Shuji Tohda et al.
LEUKEMIA RESEARCH (2006)
The regulation of INK4/ARF in cancer and aging
William Y. Kim et al.
CELL (2006)
Myc overexpression enhances apoptosis induced by small molecules
Hao Mo et al.
CELL CYCLE (2006)
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies
Karen W. L. Yee et al.
CLINICAL CANCER RESEARCH (2006)
FAS death domain deletions and cellular FADD-like interleukin 1β converting enzyme inhibitory protein (long) overexpression:: Alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes
Hidenobu Takahashi et al.
CLINICAL CANCER RESEARCH (2006)
Bcl2's flexible loop domain regulates p53 binding and survival
Xingming Deng et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation
H Mo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein
CH Lee et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes
F Feuerhake et al.
BLOOD (2005)
The p53 pathway: positive and negative feedback loops
SL Harris et al.
ONCOGENE (2005)
Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas
J Houldsworth et al.
BLOOD (2004)
The SWI/SNF complex - Chromatin and cancer
CWM Roberts et al.
NATURE REVIEWS CANCER (2004)
Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity
RT Costello et al.
LEUKEMIA (2003)
Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development
T Saito et al.
IMMUNITY (2003)
Acetylation inactivates the transcriptional repressor BCL6
OR Bereshchenko et al.
NATURE GENETICS (2002)
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts
T Berg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Toxicity and toxicokinetics of a phosphorothioate oligonucleotide against the c-myc oncogene in cynomolgus monkeys
MS Webb et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2001)
Structural basis of IAP recognition by Smac/DIABLO
G Wu et al.
NATURE (2000)
Share Paper
